STOCK TITAN

Avalyn Pharma’s Howard Lazarus sells 13,300 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Avalyn Pharma Inc. Chief Medical Officer Howard Lazarus exercised options for 13,300 shares of common stock at $4.62 per share on November 17, 2026. He sold 13,300 shares that day in three reported transactions: 11,023 at a weighted-average price of $27.8001, 2,066 at $28.2722, and 211 at $29.2722 per share. The exercise and sales were made pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. The option record reported 257,198 underlying shares following exercise; the option expires January 24, 2034.

Insider Lazarus Howard
Role Chief Medical Officer
Sold 13,300 shs ($371K)
Approx. gross sale proceeds $371K
Approx. exercise cost $61K
Approx. pre-tax spread $310K
Share of Position Sold 100%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F5 13,300 $0.00 $0.00
Exercise Common Stock F1 13,300 $4.62 $61K
Sale Common Stock F1, F2 11,023 $27.8001 $306K
Sale Common Stock F1, F3 2,066 $28.2722 $58K
Sale Common Stock F1, F4 211 $29.2722 $6K
Holdings After Transaction: Stock Option (Right to Buy) — 257,198 options (Direct); Common Stock — 0 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 270,498 to 257,198 options (Direct); Common Stock, 0 to 0 shares (Direct)
Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (5)
  1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.11 to $28.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.11 to $29.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  4. F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.13 to $29.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
  5. F5. 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Shares acquired through option exercise 13,300 shares November 17, 2026; exercise price was $4.62 per share.
Option exercise price $4.62 per share For the November 17, 2026 exercise of options for 13,300 shares.
Weighted-average sale price $27.8001 per share 11,023 shares sold on November 17, 2026; transaction prices ranged from $27.11 to $28.10.
Weighted-average sale price $28.2722 per share 2,066 shares sold on November 17, 2026; transaction prices ranged from $28.11 to $29.03.
Weighted-average sale price $29.2722 per share 211 shares sold on November 17, 2026; transaction prices ranged from $29.13 to $29.37.
Underlying shares after option exercise 257,198 shares Reported following the November 17, 2026 exercise.
Option expiration January 24, 2034 Expiration date reported for the exercised option.
Rule 10b5-1 trading plan regulatory
"pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
substantially equal monthly installments technical
"remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AVLN shares did Howard Lazarus sell, and at what prices?

Howard Lazarus sold 13,300 shares in three reported transactions on November 17, 2026: 11,023 at a weighted-average $27.8001 per share (sales ranged from $27.11 to $28.10), 2,066 at $28.2722 (range $28.11 to $29.03), and 211 at $29.2722 (range $29.13 to $29.37).

What were the vesting terms for Howard Lazarus's AVLN option?

The option vested 25% on August 7, 2024, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter, subject to Howard Lazarus's continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lazarus Howard

(Last)(First)(Middle)
C/O AVALYN PHARMA INC.
105 W FIRST STREET

(Street)
BOSTON MASSACHUSETTS 02127

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Avalyn Pharma Inc. [ AVLN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026M(1)13,300A$4.6213,300D
Common Stock11/17/2026S(1)11,023D$27.8001(2)2,277D
Common Stock11/17/2026S(1)2,066D$28.2722(3)211D
Common Stock11/17/2026S(1)211D$29.2722(4)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.6211/17/2026M(1)13,300 (5)01/24/2034Common Stock13,300$0.00257,198D
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.11 to $28.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.11 to $29.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.13 to $29.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
5. 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
/s/ Douglas Carlson, Attorney-in-Fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading